FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766841330> ?p ?o ?g. }

• W2766841330 endingPage "e67" @default.
• W2766841330 startingPage "e61" @default.
• W2766841330 abstract "VcR-CVAD was developed as an intermediate-intensity induction regimen with maintenance rituximab (MR) to improve remission durations after first-line therapy for mantle cell lymphoma (MCL) in older and younger patients with MCL.Patients with previously untreated MCL received VcR-CVAD induction chemotherapy for 6 cycles (21-day cycles). Patients achieving at least a partial response received rituximab consolidation (375 mg/m2 × 4 weekly doses) and MR (375 mg/m2 every 12 weeks × 20 doses). The primary endpoints were overall and complete response (CR), and the secondary endpoints were progression-free survival (PFS) and overall survival (OS). Thirty patients were enrolled, with a median age of 61 years. There was an even distribution of patients < 60 years and ≥ 60 years. Mantle cell lymphoma international prognostic index medium- or high-risk disease was present in 60%. The overall response rate observed was 90% (77% CR/unconfirmed CR). After a median follow-up of 7.8 years, the 6-year PFS and OS were 53% and 70%, respectively. There was no difference in 6-year PFS or OS between the younger (age < 60 years) and older (age ≥ 60 years) subgroups. In a univariate analysis, lactate dehydrogenase, when analyzed for interaction with age, had a significant effect on PFS outcomes at 6 years. There were no pretreatment variables determined to have a significant effect on OS outcomes at 6 years.Long-term outcomes with VcR-CVAD are comparable with more intensive inductions and consolidation approaches. MCL is biologically heterogeneous, and durable remission can be achieved with intermediate intensity therapy. MR appears to contribute to these excellent outcomes." @default.
• W2766841330 created "2017-11-10" @default.
• W2766841330 creator A5001986524 @default.
• W2766841330 creator A5002970130 @default.
• W2766841330 creator A5005920451 @default.
• W2766841330 creator A5012108142 @default.
• W2766841330 creator A5021263646 @default.
• W2766841330 creator A5031465905 @default.
• W2766841330 creator A5032066652 @default.
• W2766841330 creator A5042432109 @default.
• W2766841330 creator A5051310219 @default.
• W2766841330 creator A5057954884 @default.
• W2766841330 creator A5069054551 @default.
• W2766841330 creator A5086593024 @default.
• W2766841330 creator A5088771820 @default.
• W2766841330 creator A5089437249 @default.
• W2766841330 date "2018-01-01" @default.
• W2766841330 modified "2023-10-16" @default.
• W2766841330 title "VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study" @default.
• W2766841330 cites W1549556227 @default.
• W2766841330 cites W1912693401 @default.
• W2766841330 cites W1974084203 @default.
• W2766841330 cites W1996537666 @default.
• W2766841330 cites W2026003958 @default.
• W2766841330 cites W2026122699 @default.
• W2766841330 cites W2040208354 @default.
• W2766841330 cites W2056952913 @default.
• W2766841330 cites W2065464657 @default.
• W2766841330 cites W2093893201 @default.
• W2766841330 cites W2104094148 @default.
• W2766841330 cites W2105351857 @default.
• W2766841330 cites W2124235514 @default.
• W2766841330 cites W2125684345 @default.
• W2766841330 cites W2155453027 @default.
• W2766841330 cites W2156235279 @default.
• W2766841330 cites W2158945674 @default.
• W2766841330 cites W2210611916 @default.
• W2766841330 cites W2430862255 @default.
• W2766841330 cites W2470400696 @default.
• W2766841330 cites W2562452386 @default.
• W2766841330 cites W2586342709 @default.
• W2766841330 doi "https://doi.org/10.1016/j.clml.2017.10.006" @default.
• W2766841330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5896779" @default.
• W2766841330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29191715" @default.
• W2766841330 hasPublicationYear "2018" @default.
• W2766841330 type Work @default.
• W2766841330 sameAs 2766841330 @default.
• W2766841330 citedByCount "13" @default.
• W2766841330 countsByYear W27668413302018 @default.
• W2766841330 countsByYear W27668413302019 @default.
• W2766841330 countsByYear W27668413302021 @default.
• W2766841330 countsByYear W27668413302022 @default.
• W2766841330 countsByYear W27668413302023 @default.
• W2766841330 crossrefType "journal-article" @default.
• W2766841330 hasAuthorship W2766841330A5001986524 @default.
• W2766841330 hasAuthorship W2766841330A5002970130 @default.
• W2766841330 hasAuthorship W2766841330A5005920451 @default.
• W2766841330 hasAuthorship W2766841330A5012108142 @default.
• W2766841330 hasAuthorship W2766841330A5021263646 @default.
• W2766841330 hasAuthorship W2766841330A5031465905 @default.
• W2766841330 hasAuthorship W2766841330A5032066652 @default.
• W2766841330 hasAuthorship W2766841330A5042432109 @default.
• W2766841330 hasAuthorship W2766841330A5051310219 @default.
• W2766841330 hasAuthorship W2766841330A5057954884 @default.
• W2766841330 hasAuthorship W2766841330A5069054551 @default.
• W2766841330 hasAuthorship W2766841330A5086593024 @default.
• W2766841330 hasAuthorship W2766841330A5088771820 @default.
• W2766841330 hasAuthorship W2766841330A5089437249 @default.
• W2766841330 hasBestOaLocation W27668413302 @default.
• W2766841330 hasConcept C126322002 @default.
• W2766841330 hasConcept C141071460 @default.
• W2766841330 hasConcept C143998085 @default.
• W2766841330 hasConcept C144301174 @default.
• W2766841330 hasConcept C2776611710 @default.
• W2766841330 hasConcept C2776694085 @default.
• W2766841330 hasConcept C2777525834 @default.
• W2766841330 hasConcept C2778336483 @default.
• W2766841330 hasConcept C2778476033 @default.
• W2766841330 hasConcept C2779338263 @default.
• W2766841330 hasConcept C2780653079 @default.
• W2766841330 hasConcept C2780739268 @default.
• W2766841330 hasConcept C2781413609 @default.
• W2766841330 hasConcept C38180746 @default.
• W2766841330 hasConcept C71924100 @default.
• W2766841330 hasConcept C90924648 @default.
• W2766841330 hasConceptScore W2766841330C126322002 @default.
• W2766841330 hasConceptScore W2766841330C141071460 @default.
• W2766841330 hasConceptScore W2766841330C143998085 @default.
• W2766841330 hasConceptScore W2766841330C144301174 @default.
• W2766841330 hasConceptScore W2766841330C2776611710 @default.
• W2766841330 hasConceptScore W2766841330C2776694085 @default.
• W2766841330 hasConceptScore W2766841330C2777525834 @default.
• W2766841330 hasConceptScore W2766841330C2778336483 @default.
• W2766841330 hasConceptScore W2766841330C2778476033 @default.
• W2766841330 hasConceptScore W2766841330C2779338263 @default.
• W2766841330 hasConceptScore W2766841330C2780653079 @default.
• W2766841330 hasConceptScore W2766841330C2780739268 @default.
• W2766841330 hasConceptScore W2766841330C2781413609 @default.

• next